


# FORMS OF IMMUNE AUGMENTATION

## 1. FREE ANTIBODY + PEPTIDE



mAb-A (ANTI-CD3)



peptide

Jc857 U.S. PTO  
10/067104  
02/04/02

## 2. HETEROCONJUGATE (ANTIBODY-PEPTIDE)



## 3. BIFUNCTIONAL mAb/LIGAND CONJUGATE




FIGURE 1

FIGURE 2:




FIGURE 3:




FIGURE 4:




FIGURE 5 A:




FIGURE 5 B:




FIGURE 6:

ANTI-KLH ANTIBODIES IN MICE TREATED  
WITH KLH USING PBS, CFA, OR ANTI-CD3 AS IMMUNOADJUVANTS




FIGURE 7:

# ALLORESPONSE TO SEB

3H UPTAKE IN CPM




in C3H mice at 18 hr.

■ SYN    ▨ ALLO




FIGURE 8:

# IL-2R EXPRESSION ON T CELLS FROM SEB TREATED MICE (18hr.)



# PROLIFERATIVE RESPONSE TO SEB

3H UPTAKE IN CPM



in C3H mice at 18 hr. using lymph node

CONT RIL-2

FIGURE 10:







# EXPANSION OF $V_{\beta}8+$ CELLS IN SEB-TREATED MICE

DAY 3

CONTROL

(50  $\mu$ g)

(250  $\mu$ g)



LOG<sub>10</sub> FLUORESCENCE (GREEN)

LOG<sub>10</sub> FLUORESCENCE (RED)

FIGURE 11:

# LOW DOSE OKT3 - STASIK LYMPHOCYTE SUBSETS





FIGURE 12:



# ANTI-CD3 TREATMENT ABROGATES GVHD B10.BR → (B10 × B10.BR)F1 [500R]





FIGURE 14:

**ANTI-1005/45 TITER IN C57BL/10 MICE  
GIVEN 1005/45-KLH SC OR IP  
AND 145-2C11**

ANTI-1005/45 TITER



1005/45-KLH NO 2C11	SC	1005/45-KLH SC 145-2C11 4 ug IP	1005/45-KLH IP NO 2C11	1005/45-KLH IP 145-2C11 4 ug IP
------------------------	----	------------------------------------	---------------------------	------------------------------------

FIGURE 15:

IN VIVO TREATMENT WITH mAbs:

ANTI-CD3 VS. F(ab)<sup>2</sup> ANTI-CD3 x ANTI-CD4 HETEROCONJUGATE






FIGURE 16:





FIGURE 17:

TWO MODELS OF TB COLLABORATION



MHC RESTRICTED Ag RECOGNITION




FIG. 1A

mAb-A(ANTI-CD3)

PEPTIDE




FIG. 1B

mAb-B(ANTI-CD4)






FIG. 1C

1006710129001






FIG. 3




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6






FIG. 7




FIG. 9




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D

FIG. 10A-1




FIG. 10A-2




FIG. 10A-3




FIG. 10B-1




FIG. 10B-2





FIG. 10B-3



2000-03-22





FIG. 11

Country	Year	Population	Area	Population Density	Area Density
Algeria	1960	10,000,000	2,381,472	420	168
Algeria	1970	12,000,000	2,381,472	504	211
Algeria	1980	14,000,000	2,381,472	588	245
Algeria	1990	16,000,000	2,381,472	672	282
Algeria	2000	18,000,000	2,381,472	756	319
Algeria	2010	20,000,000	2,381,472	840	356
Algeria	2020	22,000,000	2,381,472	924	393
Algeria	2030	24,000,000	2,381,472	1,008	430
Algeria	2040	26,000,000	2,381,472	1,092	467
Algeria	2050	28,000,000	2,381,472	1,176	504
Algeria	2060	30,000,000	2,381,472	1,260	541
Algeria	2070	32,000,000	2,381,472	1,344	578
Algeria	2080	34,000,000	2,381,472	1,428	615
Algeria	2090	36,000,000	2,381,472	1,512	652
Algeria	2100	38,000,000	2,381,472	1,596	689
Algeria	2110	40,000,000	2,381,472	1,680	726
Algeria	2120	42,000,000	2,381,472	1,764	763
Algeria	2130	44,000,000	2,381,472	1,848	800
Algeria	2140	46,000,000	2,381,472	1,932	837
Algeria	2150	48,000,000	2,381,472	2,016	874
Algeria	2160	50,000,000	2,381,472	2,100	911
Algeria	2170	52,000,000	2,381,472	2,184	948
Algeria	2180	54,000,000	2,381,472	2,268	985
Algeria	2190	56,000,000	2,381,472	2,352	1,022
Algeria	2200	58,000,000	2,381,472	2,436	1,059
Algeria	2210	60,000,000	2,381,472	2,520	1,096
Algeria	2220	62,000,000	2,381,472	2,604	1,133
Algeria	2230	64,000,000	2,381,472	2,688	1,170
Algeria	2240	66,000,000	2,381,472	2,772	1,207
Algeria	2250	68,000,000	2,381,472	2,856	1,244
Algeria	2260	70,000,000	2,381,472	2,940	1,281
Algeria	2270	72,000,000	2,381,472	3,024	1,318
Algeria	2280	74,000,000	2,381,472	3,108	1,355
Algeria	2290	76,000,000	2,381,472	3,192	1,392
Algeria	2300	78,000,000	2,381,472	3,276	1,429
Algeria	2310	80,000,000	2,381,472	3,360	1,466
Algeria	2320	82,000,000	2,381,472	3,444	1,503
Algeria	2330	84,000,000	2,381,472	3,528	1,540
Algeria	2340	86,000,000	2,381,472	3,612	1,577
Algeria	2350	88,000,000	2,381,472	3,696	1,614
Algeria	2360	90,000,000	2,381,472	3,780	1,651
Algeria	2370	92,000,000	2,381,472	3,864	1,688
Algeria	2380	94,000,000	2,381,472	3,948	1,725
Algeria	2390	96,000,000	2,381,472	4,032	1,762
Algeria	2400	98,000,000	2,381,472	4,116	1,799
Algeria	2410	100,000,000	2,381,472	4,200	1,836
Algeria	2420	102,000,000	2,381,472	4,284	1,873
Algeria	2430	104,000,000	2,381,472	4,368	1,910
Algeria	2440	106,000,000	2,381,472	4,452	1,947
Algeria	2450	108,000,000	2,381,472	4,536	1,984
Algeria	2460	110,000,000	2,381,472	4,620	2,021
Algeria	2470	112,000,000	2,381,472		



## TREATMENT INTERVALS

FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B



~ PEPTIDE  
> m Ab

FIG. 17

